PZ0295

Tiplaxtinin

≥98% (HPLC)

• Synonym(e): (1-Benzyl-5-(4-(trifluoromethoxy)phenyl)-1H-indol-3-yl)oxoacetic acid; a-Oxo-1-(phenylmethyl)-5-[4-(trifluoromethoxy)phenyl]-1H-indole-3-acetic acid, PAI 039, PAI-039, Tiplasinin, WAY-168039
• Empirische Formel (Hill-System): C₂₄H₁₆F₃NO₄
• CAS-Nummer: 393105-53-8
• Molekulargewicht: 439.38
• MDL-Nummer: MFCD09475615
• UNSPSC-Code: 41106609
• PubChem Substanz-ID: 329823818
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 20 mg/mL, clear
• Versandbedingung: wet ice
• Lagertemp.: −20°C
• SMILES String: O=C(C(O)=O)C1=CN(CC2=CC=CC=C2)C3=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=C31
• InChI: 1S/C24H16F3NO4/c25-24(26,27)32-18-9-6-16(7-10-18)17-8-11-21-19(12-17)20(22(29)23(30)31)14-28(21)13-15-4-2-1-3-5-15/h1-12,14H,13H2,(H,30,31)
• InChIKey: ODXQFEWQSHNQNI-UHFFFAOYSA-N

Beschreibung

Biochem./physiol. Wirkung

Tiplaxtinin has high oral bioavailability. It is metabolically stable and shows large safety multiples in animal toxicology studies. Tiplaxtinin can be easily synthesized in bulk quantities. This drug also reduces diet-induced obesity in mice.

Tiplaxtinin is a potent and selective PAI-1 inhibitor. Tiplaxtinin demonstrated efficacy in vivo in multiple models of acute arterial thrombosis and has been shown to reduce physiologic PAI-1 activity.

Sicherheitshinweise

• H-Sätze: H413
• P-Sätze: P273 - P501
• Gefahreneinstufungen: Aquatic Chronic 4
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable